What is Tirzepatide?

Tirzepatide is a research peptide in the GLP-1 Metabolic class. Dual GIP/GLP-1 receptor agonist; superior weight-loss endpoints vs mono-agonism. It is studied at per-dose ranges of 2.5–15 mg / week (2.5–15 mg weekly), administered weekly sc over cycles of titration: 4 weeks per step. Supplied in Thailand by Thailand Peptides — Bangkok-based, research use only.

Single-molecule dual agonist of GIP and GLP-1 receptors. Demonstrates greater A1c and body-weight reductions than GLP-1 alone.

Published and preclinical data are summarised below; dose ranges shown reflect protocols in the research literature and should be interpreted accordingly.

How does Tirzepatide work?

Primary mechanism: Dual GIP/GLP-1 receptor agonist; superior weight-loss endpoints vs mono-agonism. Research on Tirzepatide implicates downstream effects on related signalling cascades, with magnitude and clinical relevance dependent on dose, timing, and individual pharmacogenomic factors.

Receptor binding affinity and post-receptor signalling for Tirzepatide remain areas of active investigation; several proposed effects within the GLP-1 Metabolic class are currently supported only by in-vitro or rodent data, and should be interpreted accordingly.

Tirzepatide dosage & protocol

Reference protocol for Tirzepatide (research context only, drawn from published literature):

  • Per dose: 2.5–15 mg / week
  • Weekly total: 2.5–15 mg
  • Frequency: Weekly SC
  • Cycle: Titration: 4 weeks per step

Stacking Tirzepatide

Commonly referenced pairing with Tirzepatide: Monotherapy. Stacking rationale should be grounded in complementary mechanisms, not additive speculation; interactions at shared receptors or enzymatic pathways should be accounted for. Both compounds in a Tirzepatide stack are supplied by Thailand Peptides on the same order via the Bangkok research desk.

Contraindications

MTC / MEN-2, pancreatitis. Additional caution is warranted in individuals with hepatic or renal impairment, endocrine disorders, or concurrent pharmacotherapy affecting the pathways described above.

Tirzepatide — common questions

What is Tirzepatide and what is it used for in research?
Tirzepatide is classified within the GLP-1 Metabolic group. Single-molecule dual agonist of GIP and GLP-1 receptors. Demonstrates greater A1c and body-weight reductions than GLP-1 alone. Research applications focus on the pathways outlined below. All references on this page describe published research only — Tirzepatide is supplied for in-vitro and laboratory use, not for human consumption.
How does Tirzepatide work?
Primary mechanism: Dual GIP/GLP-1 receptor agonist; superior weight-loss endpoints vs mono-agonism. Downstream effects depend on dose, timing, and the biological system under investigation. Receptor binding and post-receptor signalling for Tirzepatide remain areas of active study, and several proposed effects are supported only by preclinical data.
What is the typical Tirzepatide research dose?
Published research protocols for Tirzepatide describe per-dose ranges of 2.5–15 mg / week, with a weekly total near 2.5–15 mg, administered weekly sc. Typical cycle: titration: 4 weeks per step. These ranges reflect the literature and are not dosing recommendations for any individual.
Where can I buy Tirzepatide in Thailand?
Tirzepatide is supplied by Thailand Peptides, a Bangkok-based research-peptide supplier. Orders are placed directly via WhatsApp to the Bangkok research desk — no cart, no account, no forms. Pricing and shipping are provided on request. Open a line with the research desk →
How fast can Tirzepatide be delivered in Thailand?
Same-week delivery across Thailand is standard for orders confirmed within business hours (GMT+7, Monday–Saturday). Bangkok metro deliveries typically arrive within 1–3 business days; other provinces within 3–5. Regional Southeast Asia shipping is available on request.

Citations

  1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024
  2. Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. PMID: 34170647

References curated from PubMed. Additional literature summarised in the Thailand Peptides research library.